Sherilyn A. Tuazon

1.7k total citations · 1 hit paper
27 papers, 941 citations indexed

About

Sherilyn A. Tuazon is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Sherilyn A. Tuazon has authored 27 papers receiving a total of 941 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 13 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Sherilyn A. Tuazon's work include Multiple Myeloma Research and Treatments (17 papers), CAR-T cell therapy research (9 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Sherilyn A. Tuazon is often cited by papers focused on Multiple Myeloma Research and Treatments (17 papers), CAR-T cell therapy research (9 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Sherilyn A. Tuazon collaborates with scholars based in United States and South Africa. Sherilyn A. Tuazon's co-authors include Damian J. Green, David G. Coffey, Andrew J. Cowan, Edward N. Libby, Leona Holmberg, Ajay K. Gopal, Mary Kwok, Sarah Lee, David G. Maloney and Brian G. Till and has published in prestigious journals such as JAMA, Blood and The Lancet Oncology.

In The Last Decade

Sherilyn A. Tuazon

27 papers receiving 931 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Diagnosis and Management of Multiple Myeloma

2022 526 citations Andrew J. Cowan, Damian J. Green et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sherilyn A. Tuazon United States	10	517	494	476	128	118	27	941
Michel Delforge Belgium	17	716 1.4×	509 1.0×	486 1.0×	113 0.9×	89 0.8×	111	1.0k
Caitlin Costello United States	17	455 0.9×	519 1.1×	463 1.0×	157 1.2×	140 1.2×	64	910
Douglas W. Sborov United States	20	591 1.1×	602 1.2×	559 1.2×	149 1.2×	116 1.0×	118	1.2k
Abdul Hamid Bazarbachi United States	14	550 1.1×	479 1.0×	388 0.8×	153 1.2×	61 0.5×	30	878
Khalid Mezzi United States	12	499 1.0×	426 0.9×	411 0.9×	142 1.1×	100 0.8×	26	788
Thomas G. Martin United States	15	593 1.1×	534 1.1×	446 0.9×	138 1.1×	150 1.3×	79	946
Anna van Rhenen Netherlands	13	696 1.3×	408 0.8×	404 0.8×	300 2.3×	42 0.4×	39	1.2k
Angela Pennisi United States	15	377 0.7×	479 1.0×	345 0.7×	134 1.0×	89 0.8×	40	902
R. Angelo de Claro United States	15	154 0.3×	424 0.9×	202 0.4×	201 1.6×	62 0.5×	40	815
Larysa Sanchez United States	12	376 0.7×	335 0.7×	253 0.5×	122 1.0×	118 1.0×	65	606

Countries citing papers authored by Sherilyn A. Tuazon

Since Specialization

Citations

This map shows the geographic impact of Sherilyn A. Tuazon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sherilyn A. Tuazon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sherilyn A. Tuazon more than expected).

Fields of papers citing papers by Sherilyn A. Tuazon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sherilyn A. Tuazon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sherilyn A. Tuazon. The network helps show where Sherilyn A. Tuazon may publish in the future.

Co-authorship network of co-authors of Sherilyn A. Tuazon

This figure shows the co-authorship network connecting the top 25 collaborators of Sherilyn A. Tuazon. A scholar is included among the top collaborators of Sherilyn A. Tuazon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sherilyn A. Tuazon. Sherilyn A. Tuazon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wierda, William G., David G. Maloney, Saad S. Kenderian, et al.. (2024). CLL-184 Characteristics Associated With Response to Lisocabtagene Maraleucel (liso-cel) in Patients With R/R CLL/SLL: Exploratory Analyses From the Phase 1/2 TRANSCEND CLL 004 Study. Clinical Lymphoma Myeloma & Leukemia. 24. S346–S346. 3 indexed citations

Wierda, William G., David G. Maloney, Saad S. Kenderian, et al.. (2024). Characteristics Associated With Response to Lisocabtagene Maraleucel (liso-cel) in Patients With R/R CLL/SLL: Exploratory Analyses From the Phase 1/2 TRANSCEND CLL 004 Study. Clinical Lymphoma Myeloma & Leukemia. 24. S180–S180. 1 indexed citations

Portuguese, Andrew J., Min Fang, Sherilyn A. Tuazon, et al.. (2023). Acquired CD38 gene deletion as a mechanism of tumor antigen escape in multiple myeloma. Blood Advances. 7(23). 7235–7238. 5 indexed citations

Cowan, Andrew J., Margot J. Pont, Blythe Sather, et al.. (2023). γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. The Lancet Oncology. 24(7). 811–822. 52 indexed citations

Tuazon, Sherilyn A., Leona Holmberg, Omar Nadeem, & Paul G. Richardson. (2021). A clinical perspective on plasma cell leukemia; current status and future directions. Blood Cancer Journal. 11(2). 23–23. 32 indexed citations

Cowan, Andrew J., Margot J. Pont, Blythe Sather, et al.. (2021). Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase BCMA Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma. Blood. 138(Supplement 1). 551–551. 16 indexed citations

Cowan, Andrew J., Philip A. Stevenson, Damian J. Green, et al.. (2021). Prolonged Lenalidomide Therapy Does Not Impact Autologous Peripheral Blood Stem Cell Mobilization and Collection in Multiple Myeloma Patients: A Single-Center Retrospective Analysis. Transplantation and Cellular Therapy. 27(8). 661.e1–661.e6. 8 indexed citations

Cowan, Andrew J., Sherilyn A. Tuazon, Andrew J. Portuguese, & Damian J. Green. (2021). Chimeric Antigen Receptor T Cells for Multiple Myeloma. The Cancer Journal. 27(2). 112–118. 2 indexed citations

Cowan, Andrew J., Damian J. Green, Mehdi Karami, et al.. (2020). KRD-PACE Mobilization for Multiple Myeloma Patients With Significant Residual Disease Before Autologous Stem-Cell Transplantation. Clinical Lymphoma Myeloma & Leukemia. 20(9). 602–609. 5 indexed citations

10.

Tuazon, Sherilyn A., Ryan D. Cassaday, Theodore A. Gooley, et al.. (2020). Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma. Transplantation and Cellular Therapy. 27(1). 57.e1–57.e8. 5 indexed citations

11.

Tuazon, Sherilyn A., Brenda M. Sandmaier, Theodore A. Gooley, et al.. (2020). 90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma. Bone Marrow Transplantation. 56(1). 202–209. 13 indexed citations

12.

Chen, Jason, Tingting Zhan, Sherilyn A. Tuazon, et al.. (2019). Autologous Stem Cell Transplantation for Multiple Myeloma: Growth Factor Matters. Biology of Blood and Marrow Transplantation. 25(9). e293–e297. 6 indexed citations

13.

Tuazon, Sherilyn A., Ang Li, Theodore A. Gooley, et al.. (2019). Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B‐cell malignancies. Transfusion. 59(5). 1773–1780. 29 indexed citations

14.

O’Steen, Shyril, Melissa L. Comstock, Johnnie J. Orozco, et al.. (2019). The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model. Blood. 134(15). 1247–1256. 46 indexed citations

15.

O’Steen, Shyril, Johnnie J. Orozco, Donald K. Hamlin, et al.. (2018). The Alpha Emitter Astatine-211 Targeted to CD38 Can Eradicate Multiple Myeloma in Minimal Residual Disease Models. Blood. 132(Supplement 1). 1941–1941. 3 indexed citations

16.

Cowan, Andrew J., Zandra Klippel, Philip A. Stevenson, et al.. (2016). Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation. Amyloid. 23(4). 254–259. 5 indexed citations

17.

Cowan, Andrew J., Mehdi Karami, Edward N. Libby, et al.. (2016). Outcome of Multiple Myeloma Patients Treated with Carrd-PACE Chemomobilization: A Single-Center Experience. Blood. 128(22). 3377–3377. 2 indexed citations

18.

Tuazon, Sherilyn A., Constantine Daskalakis, Neeraj Saini, et al.. (2015). Comparison of Engraftment Syndrome with G-CSF Versus GM-CSF after Autologous Hematopoietic Progenitor Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation. 21(2). S145–S146. 3 indexed citations

19.

Tuazon, Sherilyn A., et al.. (2014). Sudden death in a patient with bone marrow transplant by a fungus among us. BMJ Case Reports. 2014. bcr2014207403–bcr2014207403. 1 indexed citations

20.

Tuazon, Sherilyn A., Manish Sharma, Tingting Zhan, et al.. (2014). Autologous Stem Cell Mobilization with Pegfilgrastim and Planned Plerixafor Is Equally Effective and Safer As Compared with Cyclophosphamide, Pegfilgrastim and Plerixafor. Biology of Blood and Marrow Transplantation. 20(2). S119–S119. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact